0	0	1998-09-22	CD	O	O	B-Num
0	1	09	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	50	CD	O	B-NP	I-Num
0	4	NEW	JJ	O	I-NP	O
0	5	TREATMENTS	NNP	O	I-NP	B-Org
0	6	ON	IN	O	B-PP	O
0	7	THE	DT	O	B-NP	O
0	8	WAY	NNP	O	I-NP	B-Org
0	9	FOR	IN	O	B-PP	I-Org
0	10	ADVANCED	NNP	O	B-NP	I-Org
0	11	DISEASE	NNP	O	O	O

1	0	WASHINGTON	NNP	O	O	B-LocStat
1	1	_	NN	O	O	O
1	2	Scientists	NNS	O	B-NP	B-ProfTitle
1	3	are	VBP	O	B-VP	O
1	4	developing	VBG	O	I-VP	O
1	5	an	DT	O	B-NP	O
1	6	array	NN	O	I-NP	O
1	7	of	IN	O	B-PP	O
1	8	new	JJ	O	B-NP	O
1	9	therapies	NNS	O	I-NP	O
1	10	for	IN	O	B-PP	O
1	11	patients	NNS	O	B-NP	O
1	12	who	WP	O	B-NP	O
1	13	fail	VBP	O	B-VP	O
1	14	frontline	NN	O	B-NP	O
1	15	prostate	NN	O	I-NP	B-Jour
1	16	cancer	NN	O	I-NP	B-Medical
1	17	treatments	NNS	O	I-NP	O
1	18	such	JJ	O	B-PP	O
1	19	as	IN	O	I-PP	O
1	20	surgery	NN	O	B-NP	O
1	21	COMMA	COMMA	O	O	O
1	22	radiation	NN	O	B-NP	O
1	23	COMMA	COMMA	O	O	O
1	24	hormonal	JJ	O	B-NP	B-Medical
1	25	blockade	NN	O	I-NP	O
1	26	and	CC	O	I-NP	O
1	27	chemotherapy	NN	O	I-NP	B-Jour
1	28	.	.	O	O	O

2	0	The	DT	O	B-NP	B-OrgCorp
2	1	National	NNP	O	I-NP	I-OrgCorp
2	2	Cancer	NNP	O	I-NP	I-OrgCorp
2	3	Institute	NNP	O	I-NP	I-OrgCorp
2	4	's	POS	O	B-NP	O
2	5	database	NN	O	I-NP	O
2	6	identifies	VBZ	O	B-VP	O
2	7	nearly	RB	O	B-NP	O
2	8	40	CD	O	I-NP	B-Num
2	9	clinical	JJ	O	I-NP	B-Medical
2	10	trials	NNS	O	I-NP	O
2	11	underway	NN	O	O	O
2	12	for	IN	O	B-PP	O
2	13	patients	NNS	O	B-NP	O
2	14	with	IN	O	B-PP	O
2	15	recurrent	JJ	O	B-NP	O
2	16	prostate	NN	O	I-NP	B-Jour
2	17	cancer	NN	O	I-NP	B-Medical
2	18	or	CC	O	I-NP	O
2	19	prostate	NN	O	I-NP	B-Jour
2	20	cancer	NN	O	I-NP	B-Medical
2	21	that	WDT	O	B-NP	O
2	22	has	VBZ	O	B-VP	O
2	23	spread	VBN	O	I-VP	O
2	24	beyond	IN	O	B-PP	O
2	25	the	DT	O	B-NP	O
2	26	gland	NN	O	I-NP	O
2	27	.	.	O	O	O

3	0	Each	DT	O	B-NP	O
3	1	clinical	JJ	O	I-NP	B-Medical
3	2	trial	NN	O	I-NP	O
3	3	has	VBZ	O	B-VP	O
3	4	its	PP$	O	B-NP	O
3	5	own	JJ	O	I-NP	O
3	6	unique	JJ	O	I-NP	O
3	7	requirements	NNS	O	I-NP	O
3	8	.	.	O	O	O

4	0	Some	DT	O	B-NP	O
4	1	demand	NN	O	I-NP	O
4	2	that	IN	O	O	O
4	3	the	DT	O	B-NP	O
4	4	patient	NN	O	I-NP	B-Medical
4	5	have	VBP	O	B-VP	O
4	6	undergone	VBN	O	I-VP	O
4	7	only	JJ	O	B-NP	O
4	8	certain	JJ	O	I-NP	O
4	9	treatments	NNS	O	I-NP	O
4	10	prior	RB	O	O	O
4	11	to	TO	O	B-PP	O
4	12	receiving	VBG	O	B-VP	O
4	13	the	DT	O	B-NP	O
4	14	experimental	JJ	O	I-NP	B-Medical
4	15	drug	NN	O	I-NP	B-Medical
4	16	.	.	O	O	O

5	0	Others	NNS	O	B-NP	O
5	1	won	VBD	O	B-VP	O
5	2	't	NN	O	B-NP	O
5	3	allow	VBP	O	B-VP	O
5	4	men	NNS	O	B-NP	O
5	5	to	TO	O	B-VP	O
5	6	participate	VB	O	I-VP	O
5	7	if	IN	O	O	O
5	8	they	PRP	O	B-NP	O
5	9	've	VBP	O	B-VP	O
5	10	had	VBD	O	I-VP	O
5	11	standard	JJ	O	B-NP	O
5	12	treatments	NNS	O	I-NP	O
5	13	within	IN	O	B-PP	O
5	14	a	DT	O	B-NP	O
5	15	certain	JJ	O	I-NP	O
5	16	timeframe	NN	O	I-NP	O
5	17	.	.	O	O	O

6	0	Experimental	JJ	O	B-NP	O
6	1	treatments	NNS	O	I-NP	O
6	2	are	VBP	O	B-VP	O
6	3	not	RB	O	O	O
6	4	without	IN	O	B-PP	O
6	5	risks	NNS	O	B-NP	O
6	6	.	.	O	O	O

7	0	There	EX	O	B-NP	O
7	1	is	VBZ	O	B-VP	O
7	2	no	DT	O	B-NP	O
7	3	guarantee	NN	O	I-NP	O
7	4	that	IN	O	O	O
7	5	they	PRP	O	B-NP	O
7	6	will	MD	O	B-VP	O
7	7	work	VB	O	I-VP	O
7	8	in	IN	O	B-PP	O
7	9	humans	NNS	O	B-NP	O
7	10	COMMA	COMMA	O	O	O
7	11	even	RB	O	O	O
7	12	though	IN	O	O	O
7	13	they	PRP	O	B-NP	O
7	14	have	VBP	O	B-VP	O
7	15	shown	VBN	O	I-VP	O
7	16	promise	VBP	O	B-VP	O
7	17	in	IN	O	B-PP	O
7	18	animals	NNS	O	B-NP	B-Animal
7	19	.	.	O	O	O

8	0	And	CC	O	O	O
8	1	the	DT	O	B-NP	O
8	2	treatments	NNS	O	I-NP	O
8	3	may	MD	O	B-VP	O
8	4	have	VB	O	I-VP	O
8	5	harmful	JJ	O	B-NP	O
8	6	side	NN	O	I-NP	O
8	7	effects	NNS	O	I-NP	O
8	8	.	.	O	O	O

9	0	Following	VBG	O	B-VP	O
9	1	are	VBP	O	B-VP	O
9	2	some	DT	O	B-NP	O
9	3	new	JJ	O	I-NP	O
9	4	prostate	NN	O	I-NP	B-Jour
9	5	cancer	NN	O	I-NP	B-Medical
9	6	treatments	NNS	O	I-NP	O
9	7	under	IN	O	O	O
9	8	study	VBP	O	O	O
9	9	along	IN	O	B-PP	O
9	10	with	IN	O	B-PP	O
9	11	contact	NN	O	B-NP	O
9	12	phone	NN	O	I-NP	O
9	13	numbers	NNS	O	I-NP	O
9	14	.	.	O	O	O

10	0	For	IN	O	B-PP	O
10	1	a	DT	O	B-NP	O
10	2	more	RBR	O	I-NP	O
10	3	complete	JJ	O	I-NP	O
10	4	listing	NN	O	I-NP	O
10	5	COMMA	COMMA	O	O	O
10	6	check	VBP	O	B-VP	O
10	7	the	DT	O	B-NP	O
10	8	Internet	NN	O	I-NP	B-OrgCorp
10	9	web	NN	O	I-NP	O
10	10	address	NN	O	I-NP	O
10	11	for	IN	O	B-PP	O
10	12	the	DT	O	B-NP	O
10	13	National	NNP	O	I-NP	B-Org
10	14	Cancer	NNP	O	I-NP	I-Org
10	15	Institute	NNP	O	I-NP	I-Org
10	16	's	POS	O	B-NP	O
10	17	clinical	JJ	O	I-NP	B-Medical
10	18	trials	NNS	O	I-NP	O
10	19	division	NN	O	I-NP	O
10	20	-LBR-	-LBR-	O	I-NP	O
10	21	http	NN	O	I-NP	O
10	22	:/cancertrials.nih.nci.gov	NN	O	O	O
10	23	-RBR-	-RBR-	O	O	O
10	24	or	CC	O	O	O
10	25	CapCure	NNP	O	B-NP	O
10	26	COMMA	COMMA	O	O	O
10	27	Michael	NNP	O	B-NP	B-Peop
10	28	Milken	NNP	O	I-NP	I-Peop
10	29	's	POS	O	B-NP	O
10	30	prostate	NN	O	I-NP	B-Jour
10	31	cancer	NN	O	I-NP	B-Jour
10	32	research	NN	O	I-NP	I-Jour
10	33	organization	NN	O	I-NP	O
10	34	-LBR-	-LBR-	O	O	O
10	35	http	NN	O	O	O
10	36	:/www.capcure.org	NN	O	O	O
10	37	-RBR-	-RBR-	O	O	O
10	38	.	.	O	O	O

11	0	Before	IN	O	B-PP	O
11	1	considering	VBG	O	B-VP	O
11	2	a	DT	O	B-NP	O
11	3	new	JJ	O	I-NP	O
11	4	treatment	NN	O	I-NP	O
11	5	that	WDT	O	B-NP	O
11	6	has	VBZ	O	B-VP	O
11	7	not	RB	O	I-VP	O
11	8	been	VBN	O	I-VP	O
11	9	FDA	NNP	O	B-NP	B-Peop
11	10	approved	VBD	O	B-VP	O
11	11	COMMA	COMMA	O	O	O
11	12	consult	VB	O	B-VP	O
11	13	your	PP$	O	B-NP	O
11	14	physician	NN	O	I-NP	B-ProfTitle
11	15	.	.	O	O	O

12	0	_	NN	O	B-NP	O
12	1	Cancer	NNP	O	I-NP	O
12	2	cell	NN	O	I-NP	O
12	3	destruction	NN	O	I-NP	O
12	4	vaccine	NN	O	I-NP	B-Medical
12	5	:	:	O	O	O
12	6	Memorial	NNP	O	B-NP	O
12	7	Sloan-Kettering	NNP	O	I-NP	O
12	8	Cancer	NNP	O	I-NP	O
12	9	Center	NNP	O	I-NP	O
12	10	in	IN	O	B-PP	O
12	11	New	NNP	O	B-NP	B-LocCit
12	12	York	NNP	O	I-NP	I-LocCit
12	13	is	VBZ	O	B-VP	O
12	14	developing	VBG	O	I-VP	O
12	15	a	DT	O	B-NP	O
12	16	vaccine	NN	O	I-NP	B-Medical
12	17	that	WDT	O	B-NP	O
12	18	will	MD	O	B-VP	O
12	19	induce	VB	O	I-VP	O
12	20	prostate	NN	O	B-NP	B-Jour
12	21	cancer	NN	O	I-NP	B-Medical
12	22	cells	NNS	O	I-NP	O
12	23	to	TO	O	B-VP	O
12	24	commit	VB	O	I-VP	O
12	25	the	DT	O	B-NP	O
12	26	cellular	JJ	O	I-NP	O
12	27	equivalent	NN	O	I-NP	O
12	28	of	IN	O	B-PP	O
12	29	suicide	NN	O	B-NP	O
12	30	.	.	O	O	O

13	0	For	IN	O	B-PP	O
13	1	information	NN	O	B-NP	O
13	2	COMMA	COMMA	O	O	O
13	3	call	VBP	O	B-VP	O
13	4	800-525-2225	CD	O	B-NP	B-Num
13	5	.	.	O	O	O

14	0	_	NN	O	O	O
14	1	Immunotherapy	NNP	O	B-NP	O
14	2	:	:	O	O	O
14	3	The	DT	O	B-NP	O
14	4	Pacific	NNP	O	I-NP	O
14	5	Northwest	NNP	O	I-NP	B-Org
14	6	Cancer	NNP	O	I-NP	I-Org
14	7	Foundation	NNP	O	I-NP	I-Org
14	8	in	IN	O	B-PP	O
14	9	Seattle	NNP	O	B-NP	B-LocCit
14	10	is	VBZ	O	B-VP	O
14	11	developing	VBG	O	I-VP	O
14	12	a	DT	O	B-NP	O
14	13	vaccine	NN	O	I-NP	B-Medical
14	14	to	TO	O	B-VP	O
14	15	jump-start	VB	O	I-VP	O
14	16	the	DT	O	B-NP	O
14	17	body	NN	O	I-NP	O
14	18	's	POS	O	B-NP	O
14	19	immune	JJ	O	I-NP	B-Medical
14	20	system	NN	O	I-NP	O
14	21	to	TO	O	B-VP	O
14	22	attack	VB	O	I-VP	O
14	23	prostate	NN	O	B-NP	B-Jour
14	24	cancer	NN	O	I-NP	B-Medical
14	25	cells	NNS	O	I-NP	O
14	26	.	.	O	O	O

15	0	Researchers	NNS	O	B-NP	B-ProfTitle
15	1	take	VBP	O	B-VP	O
15	2	a	DT	O	B-NP	O
15	3	sampling	NN	O	I-NP	O
15	4	of	IN	O	B-PP	O
15	5	a	DT	O	B-NP	O
15	6	patient	NN	O	I-NP	B-Medical
15	7	's	POS	O	B-NP	O
15	8	blood	NN	O	I-NP	O
15	9	COMMA	COMMA	O	O	O
15	10	then	RB	O	O	O
15	11	isolate	VBP	O	B-VP	O
15	12	and	CC	O	O	O
15	13	multiply	VB	O	B-VP	O
15	14	immune	JJ	O	B-NP	B-Medical
15	15	system	NN	O	I-NP	O
15	16	foot	NN	O	I-NP	B-NumUnit
15	17	soldiers	NNS	O	I-NP	O
15	18	known	VBN	O	B-VP	O
15	19	as	IN	O	B-PP	O
15	20	dendritic	JJ	O	B-NP	B-Medical
15	21	cells	NNS	O	I-NP	O
15	22	.	.	O	O	O

16	0	These	DT	O	B-NP	O
16	1	are	VBP	O	B-VP	O
16	2	injected	VBN	O	I-VP	O
16	3	back	RB	O	O	O
16	4	into	IN	O	B-PP	O
16	5	the	DT	O	B-NP	O
16	6	patient	NN	O	I-NP	B-Medical
16	7	where	WRB	O	O	O
16	8	they	PRP	O	B-NP	O
16	9	spark	VBP	O	B-VP	O
16	10	the	DT	O	B-NP	O
16	11	production	NN	O	I-NP	O
16	12	of	IN	O	B-PP	O
16	13	cancer-killing	JJ	O	B-NP	O
16	14	cells	NNS	O	I-NP	O
16	15	COMMA	COMMA	O	O	O
16	16	which	WDT	O	B-NP	O
16	17	then	RB	O	O	O
16	18	travel	VBP	O	B-VP	O
16	19	throughout	IN	O	B-PP	O
16	20	the	DT	O	B-NP	O
16	21	body	NN	O	I-NP	O
16	22	hunting	NN	O	I-NP	B-Sport
16	23	down	IN	O	O	O
16	24	prostate	NN	O	B-NP	B-Jour
16	25	cancer	NN	O	I-NP	B-Medical
16	26	cells	NNS	O	I-NP	O
16	27	.	.	O	O	O

17	0	For	IN	O	B-PP	O
17	1	information	NN	O	B-NP	O
17	2	COMMA	COMMA	O	O	O
17	3	call	VBP	O	B-VP	O
17	4	1-800-MED-INFO	NN	O	B-NP	B-Num
17	5	.	.	O	O	O

18	0	_	NN	O	O	O
18	1	Starving	NNP	O	B-NP	O
18	2	the	DT	O	B-NP	O
18	3	cancer	NN	O	I-NP	B-Medical
18	4	:	:	O	O	O
18	5	The	DT	O	B-NP	O
18	6	University	NNP	O	I-NP	B-OrgUniv
18	7	of	IN	O	B-PP	I-OrgUniv
18	8	California	NNP	O	B-NP	I-OrgUniv
18	9	at	IN	O	B-PP	O
18	10	San	NNP	O	B-NP	B-LocCit
18	11	Francisco	NNP	O	I-NP	I-LocCit
18	12	is	VBZ	O	B-VP	O
18	13	developing	VBG	O	I-VP	O
18	14	an	DT	O	B-NP	O
18	15	antibody	NN	O	I-NP	B-Medical
18	16	to	TO	O	B-VP	O
18	17	disrupt	VB	O	I-VP	O
18	18	blood	NN	O	B-NP	O
18	19	vessel	NN	O	I-NP	O
18	20	flow	NN	O	I-NP	O
18	21	to	TO	O	B-PP	O
18	22	prostate	NN	O	B-NP	B-Jour
18	23	cancer	NN	O	I-NP	B-Medical
18	24	cells	NNS	O	I-NP	O
18	25	.	.	O	O	O

19	0	The	DT	O	B-NP	O
19	1	idea	NN	O	I-NP	O
19	2	is	VBZ	O	B-VP	O
19	3	that	IN	O	O	O
19	4	lacking	VBG	O	B-VP	O
19	5	blood	NN	O	B-NP	O
19	6	COMMA	COMMA	O	O	O
19	7	the	DT	O	O	O
19	8	malignancy	NN	O	O	O
19	9	will	NN	O	B-VP	O
19	10	slow	VB	O	I-VP	O
19	11	or	CC	O	O	O
19	12	stop	VBP	O	B-VP	O
19	13	growing	VBG	O	I-VP	O
19	14	.	.	O	O	O

20	0	For	IN	O	B-PP	O
20	1	information	NN	O	B-NP	O
20	2	call	VBP	O	B-VP	O
20	3	415-885-7331	CD	O	B-NP	B-Num
20	4	.	.	O	O	O

21	0	_	NN	O	B-NP	O
21	1	Gene	NNP	O	I-NP	O
21	2	Therapy	NNP	O	I-NP	O
21	3	:	:	O	O	O
21	4	Researchers	NNS	O	B-NP	B-ProfTitle
21	5	at	IN	O	B-PP	O
21	6	George	NNP	O	B-NP	B-OrgUniv
21	7	Washington	NNP	O	I-NP	I-OrgUniv
21	8	University	NNP	O	I-NP	I-OrgUniv
21	9	in	IN	O	B-PP	O
21	10	Washington	NNP	O	B-NP	B-LocCit
21	11	COMMA	COMMA	O	O	O
21	12	D.C.	NNP	O	B-NP	B-LocStat
21	13	COMMA	COMMA	O	O	O
21	14	have	VBP	O	B-VP	O
21	15	discovered	VBN	O	I-VP	O
21	16	that	IN	O	O	O
21	17	prostate	NN	O	B-NP	B-Jour
21	18	cells	NNS	O	I-NP	O
21	19	lacking	VBG	O	B-VP	O
21	20	the	DT	O	B-NP	O
21	21	uteroglobin	NN	O	I-NP	O
21	22	protein	NN	O	I-NP	B-Medical
21	23	are	VBP	O	B-VP	O
21	24	likely	JJ	O	O	O
21	25	to	TO	O	B-VP	O
21	26	have	VB	O	I-VP	O
21	27	a	DT	O	O	O
21	28	rapidly	RB	O	O	O
21	29	advancing	VBG	O	O	O
21	30	cancer	NN	O	B-NP	B-Medical
21	31	.	.	O	O	O

22	0	Still	RB	O	O	O
22	1	about	IN	O	B-NP	O
22	2	18	CD	O	I-NP	B-Num
22	3	months	NNS	O	I-NP	I-Num
22	4	away	RB	O	O	O
22	5	from	IN	O	B-PP	O
22	6	human	JJ	O	B-NP	B-Animal
22	7	trials	NNS	O	I-NP	O
22	8	COMMA	COMMA	O	O	O
22	9	scientists	NNS	O	B-NP	B-ProfTitle
22	10	are	VBP	O	B-VP	O
22	11	devising	VBG	O	I-VP	O
22	12	a	DT	O	B-NP	O
22	13	treatment	NN	O	I-NP	O
22	14	to	TO	O	B-VP	O
22	15	inject	VB	O	I-VP	O
22	16	the	DT	O	B-NP	O
22	17	protein	NN	O	I-NP	B-Medical
22	18	back	NN	O	O	O
22	19	into	IN	O	B-PP	O
22	20	cells	NNS	O	B-NP	O
22	21	in	IN	O	B-PP	O
22	22	an	DT	O	B-NP	O
22	23	effort	NN	O	I-NP	O
22	24	to	TO	O	B-VP	O
22	25	slow	VB	O	I-VP	O
22	26	the	DT	O	B-NP	O
22	27	spread	NN	O	I-NP	O
22	28	.	.	O	O	O

23	0	_	NN	O	O	O
23	1	Cancer-Killing	NNP	O	B-NP	O
23	2	Virus	NNP	O	I-NP	O
23	3	:	:	O	O	O
23	4	Researchers	NNS	O	B-NP	B-ProfTitle
23	5	at	IN	O	B-PP	O
23	6	the	DT	O	B-NP	O
23	7	University	NNP	O	I-NP	B-OrgUniv
23	8	of	IN	O	B-PP	I-OrgUniv
23	9	California	NNP	O	B-NP	I-OrgUniv
23	10	at	IN	O	B-PP	O
23	11	San	NNP	O	B-NP	B-LocCit
23	12	Francisco	NNP	O	I-NP	I-LocCit
23	13	and	CC	O	O	O
23	14	John	NNP	O	B-NP	O
23	15	Hopkins	NNP	O	I-NP	O
23	16	University	NNP	O	I-NP	B-OrgUniv
23	17	in	IN	O	B-PP	O
23	18	Baltimore	NNP	O	B-NP	B-LocCit
23	19	are	VBP	O	B-VP	O
23	20	creating	VBG	O	I-VP	O
23	21	a	DT	O	B-NP	O
23	22	new	JJ	O	I-NP	O
23	23	kind	NN	O	I-NP	O
23	24	of	IN	O	B-PP	O
23	25	genetically	RB	O	B-NP	O
23	26	altered	VBN	O	I-NP	O
23	27	virus	NN	O	I-NP	O
23	28	to	TO	O	B-VP	O
23	29	seek	VB	O	I-VP	O
23	30	out	IN	O	O	O
23	31	and	CC	O	O	O
23	32	kill	VBP	O	B-VP	O
23	33	prostate	NN	O	B-NP	B-Jour
23	34	cancer	NN	O	I-NP	B-Medical
23	35	cells	NNS	O	I-NP	O
23	36	.	.	O	O	O

24	0	For	IN	O	B-PP	O
24	1	information	NN	O	B-NP	O
24	2	call	VBP	O	B-VP	O
24	3	UCSF	NNP	O	B-NP	O
24	4	at	IN	O	B-PP	O
24	5	415-885-7331	CD	O	B-NP	B-Num
24	6	or	CC	O	O	O
24	7	Johns	NNP	O	B-NP	B-Peop
24	8	Hopkins	NNP	O	I-NP	I-Peop
24	9	at	IN	O	B-PP	O
24	10	410-955-8964	CD	O	B-NP	B-Num
24	11	.	.	O	O	O

25	0	_	NN	O	O	O
25	1	Metastatic	NNP	O	B-NP	O
25	2	treatments	NNS	O	I-NP	O
25	3	:	:	O	O	O
25	4	When	WRB	O	O	O
25	5	it	PRP	O	B-NP	O
25	6	spreads	VBZ	O	B-VP	O
25	7	and	CC	O	I-VP	O
25	8	enters	VBZ	O	I-VP	O
25	9	the	DT	O	B-NP	O
25	10	lethal	JJ	O	I-NP	B-Medical
25	11	stages	NNS	O	I-NP	O
25	12	COMMA	COMMA	O	O	O
25	13	prostate	NN	O	B-NP	B-Jour
25	14	cancer	NN	O	I-NP	B-Medical
25	15	typically	RB	O	O	O
25	16	travels	VBZ	O	B-VP	O
25	17	to	TO	O	B-PP	O
25	18	bone	NN	O	B-NP	O
25	19	where	WRB	O	O	O
25	20	it	PRP	O	B-NP	O
25	21	grows	VBZ	O	B-VP	O
25	22	and	CC	O	I-VP	O
25	23	kills	VBZ	O	I-VP	O
25	24	the	DT	O	B-NP	O
25	25	patient	NN	O	I-NP	B-Medical
25	26	.	.	O	O	O

26	0	Researchers	NNS	O	B-NP	B-ProfTitle
26	1	at	IN	O	B-PP	O
26	2	the	DT	O	B-NP	O
26	3	University	NNP	O	I-NP	B-OrgUniv
26	4	of	IN	O	B-PP	I-OrgUniv
26	5	Wisconsin	NNP	O	B-NP	I-OrgUniv
26	6	-LBR-	-LBR-	O	O	O
26	7	608-263-7107	CD	O	O	B-Num
26	8	-RBR-	-RBR-	O	O	O
26	9	COMMA	COMMA	O	O	O
26	10	University	NNP	O	O	B-OrgUniv
26	11	of	IN	O	B-PP	I-OrgUniv
26	12	Virginia	NNP	O	B-NP	I-OrgUniv
26	13	-LBR-	-LBR-	O	O	O
26	14	804-243-6188	CD	O	O	B-Num
26	15	-RBR-	-RBR-	O	O	O
26	16	and	CC	O	O	O
26	17	M.D	NNP	O	B-NP	B-Org
26	18	.	.	O	O	O

27	0	Anderson	NNP	O	O	B-Org
27	1	Cancer	NNP	O	O	I-Org
27	2	Center	NNP	O	O	I-Org
27	3	in	IN	O	B-PP	O
27	4	Houston	NNP	O	B-NP	B-LocCit
27	5	-LBR-	-LBR-	O	O	O
27	6	800-392-1611	CD	O	O	B-Num
27	7	-RBR-	-RBR-	O	O	O
27	8	are	VBP	O	B-VP	O
27	9	developing	VBG	O	I-VP	O
27	10	treatments	NNS	O	B-NP	O
27	11	to	TO	O	B-VP	O
27	12	halt	VB	O	I-VP	O
27	13	this	DT	O	B-NP	O
27	14	deadly	JJ	O	I-NP	O
27	15	migratory	JJ	O	I-NP	O
27	16	pattern	NN	O	I-NP	O
27	17	.	.	O	O	O

28	0	_	NN	O	O	O
28	1	New	NNP	O	B-NP	O
28	2	chemotherapies	NNS	O	I-NP	O
28	3	:	:	O	O	O
28	4	Chemotherapy	NNP	O	B-NP	B-Peop
28	5	is	VBZ	O	B-VP	O
28	6	a	DT	O	B-NP	O
28	7	last	JJ	O	I-NP	O
28	8	resort	NN	O	I-NP	O
28	9	because	IN	O	O	O
28	10	prostate	NN	O	B-NP	B-Jour
28	11	cancer	NN	O	I-NP	B-Medical
28	12	usually	RB	O	O	O
28	13	doesn	NN	O	B-NP	O
28	14	't	NN	O	I-NP	O
28	15	respond	VBP	O	B-VP	O
28	16	to	TO	O	B-PP	O
28	17	toxins	NNS	O	B-NP	O
28	18	.	.	O	O	O

29	0	But	CC	O	O	O
29	1	scientists	NNS	O	B-NP	B-ProfTitle
29	2	are	VBP	O	B-VP	O
29	3	making	VBG	O	I-VP	O
29	4	strides	NNS	O	B-NP	O
29	5	combining	VBG	O	B-VP	O
29	6	toxins	NNS	O	B-NP	O
29	7	COMMA	COMMA	O	O	O
29	8	hormonal	JJ	O	B-NP	B-Medical
29	9	blockade	NN	O	I-NP	O
29	10	drugs	NNS	O	I-NP	O
29	11	and	CC	O	O	O
29	12	other	JJ	O	B-NP	O
29	13	compounds	NNS	O	I-NP	O
29	14	.	.	O	O	O

30	0	Compared	VBN	O	B-PP	O
30	1	with	IN	O	B-PP	O
30	2	traditional	JJ	O	B-NP	O
30	3	chemo	NN	O	I-NP	O
30	4	COMMA	COMMA	O	O	O
30	5	the	DT	O	B-NP	O
30	6	combination	NN	O	I-NP	B-Medical
30	7	is	VBZ	O	B-VP	O
30	8	better	RBR	O	O	O
30	9	able	JJ	O	O	O
30	10	to	TO	O	B-VP	O
30	11	target	VB	O	I-VP	O
30	12	and	CC	O	O	O
30	13	kill	VBP	O	B-VP	O
30	14	prostate	NN	O	B-NP	B-Jour
30	15	cancer	NN	O	I-NP	B-Medical
30	16	cells	NNS	O	I-NP	O
30	17	while	IN	O	O	O
30	18	minimizing	VBG	O	B-VP	O
30	19	damage	NN	O	B-NP	O
30	20	to	TO	O	B-PP	O
30	21	healthy	JJ	O	B-NP	O
30	22	cells	NNS	O	I-NP	O
30	23	.	.	O	O	O

31	0	Several	JJ	O	B-NP	O
31	1	institutions	NNS	O	I-NP	O
31	2	are	VBP	O	B-VP	O
31	3	spearheading	VBG	O	I-VP	O
31	4	the	DT	O	B-NP	O
31	5	new	JJ	O	I-NP	O
31	6	treatments	NNS	O	I-NP	O
31	7	COMMA	COMMA	O	O	O
31	8	including	VBG	O	B-PP	O
31	9	M.D	NNP	O	B-NP	B-Loc
31	10	.	.	O	O	O

32	0	Anderson	NNP	O	O	B-Org
32	1	Cancer	NNP	O	O	I-Org
32	2	Center	NNP	O	O	I-Org
32	3	-LBR-	-LBR-	O	O	O
32	4	800-392-1611	CD	O	O	B-Num
32	5	-RBR-	-RBR-	O	O	O
32	6	COMMA	COMMA	O	O	O
32	7	the	DT	O	B-NP	O
32	8	University	NNP	O	I-NP	B-OrgUniv
32	9	of	IN	O	B-PP	I-OrgUniv
32	10	Michigan	NNP	O	B-NP	I-OrgUniv
32	11	-LBR-	-LBR-	O	O	O
32	12	800-865-1125	CD	O	O	B-Num
32	13	-RBR-	-RBR-	O	O	O
32	14	and	CC	O	O	O
32	15	Memorial	NNP	O	B-NP	B-Peop
32	16	Sloan	NNP	O	I-NP	I-Peop
32	17	Kettering	NNP	O	I-NP	I-Peop
32	18	-LBR-	-LBR-	O	O	O
32	19	800-525-2225	CD	O	O	B-Num
32	20	-RBR-	-RBR-	O	O	O
32	21	.	.	O	O	O

33	0	_	NN	O	O	O
33	1	Alternative	JJ	O	O	O
33	2	remedies	NNS	O	O	O
33	3	:	:	O	O	O
33	4	PC	NN	O	B-NP	B-OrgCorp
33	5	Spes	NNP	O	I-NP	O
33	6	COMMA	COMMA	O	O	O
33	7	a	DT	O	B-NP	O
33	8	mixture	NN	O	I-NP	O
33	9	of	IN	O	B-PP	O
33	10	chemical	NN	O	B-NP	B-Medical
33	11	compounds	NNS	O	I-NP	O
33	12	extracted	VBN	O	B-VP	O
33	13	from	IN	O	B-PP	O
33	14	several	JJ	O	B-NP	O
33	15	Chinese	JJ	O	I-NP	B-LangRace
33	16	herbs	NNS	O	I-NP	O
33	17	COMMA	COMMA	O	O	O
33	18	is	VBZ	O	B-VP	O
33	19	one	CD	O	B-NP	B-Num
33	20	of	IN	O	B-PP	O
33	21	the	DT	O	B-NP	O
33	22	most	JJS	O	I-NP	O
33	23	talked-about	JJ	O	I-NP	O
33	24	alternative	JJ	O	I-NP	B-Medical
33	25	treatments	NNS	O	I-NP	O
33	26	for	IN	O	B-PP	O
33	27	prostate	NN	O	B-NP	B-Jour
33	28	cancer	NN	O	I-NP	B-Medical
33	29	.	.	O	O	O

34	0	The	DT	O	B-NP	O
34	1	treatment	NN	O	I-NP	O
34	2	COMMA	COMMA	O	O	O
34	3	which	WDT	O	B-NP	O
34	4	is	VBZ	O	B-VP	O
34	5	designed	VBN	O	I-VP	O
34	6	to	TO	O	I-VP	O
34	7	cause	VB	O	I-VP	O
34	8	prostate	NN	O	B-NP	B-Jour
34	9	cancer	NN	O	I-NP	B-Medical
34	10	cells	NNS	O	I-NP	O
34	11	to	TO	O	B-PP	O
34	12	self-destruct	NN	O	B-NP	O
34	13	COMMA	COMMA	O	O	O
34	14	is	VBZ	O	B-VP	O
34	15	receiving	VBG	O	I-VP	O
34	16	serious	JJ	O	B-NP	O
34	17	attention	NN	O	I-NP	O
34	18	at	IN	O	B-PP	O
34	19	the	DT	O	B-NP	O
34	20	University	NNP	O	I-NP	B-OrgUniv
34	21	of	IN	O	B-PP	I-OrgUniv
34	22	California	NNP	O	B-NP	I-OrgUniv
34	23	at	IN	O	B-PP	O
34	24	San	NNP	O	B-NP	B-LocCit
34	25	Francisco	NNP	O	I-NP	I-LocCit
34	26	COMMA	COMMA	O	O	O
34	27	which	WDT	O	B-NP	O
34	28	is	VBZ	O	B-VP	O
34	29	scheduled	VBN	O	I-VP	O
34	30	to	TO	O	I-VP	O
34	31	begin	VB	O	I-VP	O
34	32	a	DT	O	B-NP	O
34	33	clinical	JJ	O	I-NP	B-Medical
34	34	trial	NN	O	I-NP	O
34	35	on	IN	O	B-PP	O
34	36	it	PRP	O	B-NP	O
34	37	.	.	O	O	O

35	0	For	IN	O	B-PP	O
35	1	more	JJR	O	B-NP	O
35	2	information	NN	O	I-NP	O
35	3	call	VBP	O	B-VP	O
35	4	the	DT	O	B-NP	O
35	5	treatment	NN	O	I-NP	O
35	6	's	POS	O	B-NP	O
35	7	Brea	NNP	O	I-NP	B-LocCit
35	8	COMMA	COMMA	O	I-NP	O
35	9	Calif.	NNP	O	I-NP	B-LocStat
35	10	-	:	O	O	O
35	11	based	VBN	O	B-NP	O
35	12	distributor	NN	O	I-NP	B-ProfTitle
35	13	COMMA	COMMA	O	O	O
35	14	Botanic	NNP	O	B-NP	B-Peop
35	15	Lab	NNP	O	I-NP	I-Peop
35	16	COMMA	COMMA	O	O	O
35	17	at	IN	O	B-PP	O
35	18	800-242-5555	CD	O	B-NP	B-Num
35	19	.	.	O	O	O
